Cover ImageSALE
Market Research Report

Global Infertility Drugs Market 2018-2022

Published by TechNavio (Infiniti Research Ltd.) Product code 603596
Published Content info 114 Pages
Immediate Delivery Available
Price
Back to Top
Global Infertility Drugs Market 2018-2022
Published: February 5, 2018 Content info: 114 Pages
Description

About Infertility Drugs

Infertility can be defined as an inability of a person to reproduce through natural means. Infertility can occur in any of the two genders, i.e., male and female.

Technavio's analysts forecast the global infertility drugs market to grow at a CAGR of 4.67% during the period 2018-2022.

Covered in this report

The report covers the present scenario and the growth prospects of the global infertility drugs market for 2018-2022. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Infertility Drugs Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Bayer
  • Ferring
  • Merck
  • Novartis

Market driver

  • Growing lifestyle diseases
  • For a full, detailed list, view our report

Market challenge

  • Rising inclination toward other modes of treatment for infertility
  • For a full, detailed list, view our report

Market trend

  • Raising awareness regarding infertility in couples
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents
Product Code: IRTNTR20633

Table of Contents

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION

  • Introduction
  • Diagnosis and treatment

PART 05: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 06: MARKET SIZING

  • Market definition
  • Market sizing
  • Market size and forecast

PART 07: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 08: PIPELINE ANALYSIS

PART 09: MARKET SEGMENTATION BY THERAPY

  • Segmentation by therapy
  • Comparison by therapy
  • Global hormone-based therapy market
  • Global others market
  • Market opportunity by therapy

PART 10: MARKET SEGMENTATION BY GENDER

  • Segmentation by gender
  • Global female infertility drugs market
  • Global male infertility drugs market

PART 11: CUSTOMER LANDSCAPE

PART 12: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Infertility drugs market in Americas
  • Infertility drugs market in EMEA
  • Infertility drugs market in APAC
  • Market opportunity

PART 13: DECISION FRAMEWORK

PART 14: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 15: MARKET TRENDS

  • Raising awareness regarding infertility in couples
  • Growing online retail sales of drugs

PART 16: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 17: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bayer
  • Ferring
  • Merck
  • Novartis

PART 18: APPENDIX

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Definition of infertility in different genders
  • Exhibit 02: Fertility rates, 2015
  • Exhibit 03: Parent market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition: Inclusions and exclusions checklist
  • Exhibit 07: Market size 2017
  • Exhibit 08: Validation techniques employed for market sizing 2017
  • Exhibit 09: Global infertility drugs market 2017-2022 ($ millions)
  • Exhibit 10: Major factors affecting the global infertility drugs market 2017
  • Exhibit 11: Global infertility drugs market: Year-over-year (YoY) growth 2018-2022 (%)
  • Exhibit 12: Five forces analysis 2017
  • Exhibit 13: Five forces analysis 2022
  • Exhibit 14: Bargaining power of buyers
  • Exhibit 15: Bargaining power of suppliers
  • Exhibit 16: Threat of new entrants
  • Exhibit 17: Threat of substitutes
  • Exhibit 18: Threat of rivalry
  • Exhibit 19: Market condition: Five forces 2017
  • Exhibit 20: Pipeline analysis by development phase
  • Exhibit 21: Key clinical trials
  • Exhibit 22: Segmentation of global infertility drugs market by therapy 2017-2022 (%)
  • Exhibit 23: Comparison by therapy
  • Exhibit 24: Global hormone-based therapy market 2017-2022 ($ millions)
  • Exhibit 25: Hormonal therapy for infertility
  • Exhibit 26: Global hormone-based therapy market: Y0Y growth 2018-2022 (%)
  • Exhibit 27: Global others market 2017-2022 ($ millions)
  • Exhibit 28: Global others market: YoY growth 2018-2022 (%)
  • Exhibit 29: Market opportunity by therapy
  • Exhibit 30: Segmentation of global infertility drugs market by gender 2017
  • Exhibit 31: Customer landscape
  • Exhibit 32: Global infertility drugs market share by geography 2017-2022 (%)
  • Exhibit 33: Regional comparison
  • Exhibit 34: Infertility drugs market in Americas 2017-2022 ($ millions)
  • Exhibit 35: Infertility drugs market in Americas: YoY growth 2018-2022 (%)
  • Exhibit 36: Fertility rate in top three countries in Americas 1960-2015
  • Exhibit 37: Top three countries in Americas
  • Exhibit 38: Infertility drugs market in EMEA 2017-2022 ($ millions)
  • Exhibit 39: Infertility drugs market in EMEA: YoY growth 2018-2022 (%)
  • Exhibit 40: Fertility rate in top three countries in EMEA 1960-2015
  • Exhibit 41: Top three countries in EMEA
  • Exhibit 42: Infertility drugs market in APAC 2017-2022 ($ millions)
  • Exhibit 43: Infertility drugs market in APAC: YoY growth 2018-2022 (%)
  • Exhibit 44: Fertility rate in top three countries in APAC 1960-2015
  • Exhibit 45: Top three countries in APAC
  • Exhibit 46: Market opportunity
  • Exhibit 47: Pregnancy complications in diabetic women after embryo implantation
  • Exhibit 48: Diabetes effect on men fertility
  • Exhibit 49: Global fertility rate
  • Exhibit 50: Demographic and economic snapshot of India and China
  • Exhibit 51: Non-therapeutic mode of infertility treatment
  • Exhibit 52: Side effects of medications used in infertility treatment
  • Exhibit 53: Vendor landscape
  • Exhibit 54: Landscape disruption
  • Exhibit 55: Vendors covered
  • Exhibit 56: Vendor classification
  • Exhibit 57: Market positioning of vendors
  • Exhibit 58: Bayer: Vendor overview
  • Exhibit 59: Bayer: Business segments
  • Exhibit 60: Bayer: Organizational developments
  • Exhibit 61: Bayer: Geographic focus
  • Exhibit 62: Bayer: Segment focus
  • Exhibit 63: Bayer: Key offerings
  • Exhibit 64: Ferring: Vendor overview
  • Exhibit 65: Ferring: Business segments
  • Exhibit 66: Ferring: Organizational developments
  • Exhibit 67: Ferring: Geographic focus
  • Exhibit 68: Ferring: Segment focus
  • Exhibit 69: Ferring: Key offerings
  • Exhibit 70: Merck: Vendor overview
  • Exhibit 71: Merck: Business segments
  • Exhibit 72: Merck: Organizational developments
  • Exhibit 73: Merck: Geographic focus
  • Exhibit 74: Merck: Segment focus
  • Exhibit 75: Merck: Key offerings
  • Exhibit 76: Novartis: Vendor overview
  • Exhibit 77: Novartis: Business segments
  • Exhibit 78: Novartis: Organizational developments
  • Exhibit 79: Novartis: Geographic focus
  • Exhibit 80: Novartis: Segment focus
  • Exhibit 81: Novartis: Key offerings
Back to Top